Here are four things to know about the new steps.
1. The FDA established a 23-item questionnaire to measure health information from patients with heart failure. The questionnaire, called a medical device development tool, will provide an objective platform to facilitate the development of devices for cardiovascular health.
2. The agency will also issue three new guidance documents for medical device manufacturers.
3. The first draft guidance enables a quicker pre-submission process for breakthrough drugs under the FDA’s Breakthrough Devices Program. This program was recently established to help patients more quickly access certain devices for life-threatening or debilitating diseases.
4. The other two documents modify the 510(k) notification process. The 510(k) notification is a premarket submission made the FDA to demonstrate the device will be marketed safely and effectively, according to the FDA website.
More articles on supply chain:
Survey: 61% of patient advocacy groups have favorable view of devicemakers
Baxter expects $70M revenue loss from Hurricane Maria
Survey: 61% of patient advocacy groups have favorable view of devicemakers
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
